A key challenge for elimination of malaria in the Asia-Pacific and the Americas is the high proportion of infections caused by Plasmodium vivax. This is due to a hidden parasite stage in the liver, hypnozoites, that are responsible for maintaining transmission in communities. To overcome this hurdle, we need innovative tools that specifically detect people with hidden P. vivax hypnozoites. Our novel strategy is to measure antibodies induced in response to infection, rather than the parasites themselves. Through studies in the Asia-Pacific and Americas, we identified and validated a novel panel of serological markers of recent infection. Our data demonstrates that these markers can identify individuals at risk of recurrent P. vivax infections. In addition to testing the serological markers in multiple geographic settings, we have also explicitly assessed patterns of genetic diversity and immune selective pressure within the leading antigens. Whilst several antigens had high levels of diversity, the antibody response performance was only altered by one antigen, which was subsequently dropped from the panel. To translate our findings and accelerate malaria elimination in our region we have established the “Vivax Serology Partnership” (VISPA). The major objective of VISPA is to provide the evidence to introduce serological surveillance and targeted drug treatment interventions into global national policy, as well as supporting technological development. The latter includes identification of monoclonal antibodies against the antigen panel as controls. This presentation will introduce both the immunology behind this invention and the progress towards translation into a novel public health intervention.